

## Special Issue

# Advances in Precision Medicine: Targeting Known and Emerging Oncogenic Targets in Lung Cancer

### Message from the Guest Editor

The current era of precision medicine in resectable early-stage and non-operable advanced-stage NSCLC mandates the pathohistological evaluation and molecular biomarker testing of tumor specimens at diagnosis. Increasingly, subsequent biomarker testing is essential for selecting appropriate treatment at timepoints of tumor progression throughout the disease course. Significant progress has also been made in expanding the armamentarium of targeted therapies from small molecule tyrosine kinase inhibitors and monoclonal antibodies to covalent bound inhibitors, bispecific antibodies, and antibody–drug conjugants for both known and emerging oncogenic targets. The clinical implementation of precision medicine in lung cancer requires the close collaboration of a multidisciplinary team. This Special Issue will focus on a series of reviews on recent advances in targeting known and emerging oncogenic targets (such as MET, HER2, and KRAS genomic alterations) in lung adenocarcinomas, lung squamous cell carcinoma, neuroendocrine, small cell lung cancer, and malignant pleural mesothelioma.

### Guest Editor

Prof. Dr. Tianhong Li

Division of Hematology/Oncology, Department of Internal Medicine,  
University of California Davis Comprehensive Cancer Center,  
Sacramento, CA, USA

### Deadline for manuscript submissions

closed (20 March 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/151933](https://mdpi.com/si/151933)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)